AdvisorShares Psychedelics ETF (ARCA: PSIL)

에 대한 최신 뉴스 AdvisorShares Psychedelics ETF (ARCA:PSIL)

AdvisorShares Psychedelics ETF

Healthcare

Other

The Fund is an actively managed exchange-traded fund (ETF) that seeks to achieve its investment objective by primarily investing in publicly listed life sciences companies focused on psychedelic medicines as well as other companies with activities in the psychedelics business. The Fund invests in exchange-listed equity securities, including common and preferred stock of U.S. and foreign mid-, small- and micro-capitalization companies, and in total return swaps intended to provide exposure to such companies. Under normal circumstances, Fund invests at least 80 percent of its net assets (plus any borrowings for investment purposes) in (i) securities of companies that derive at least 50 percent of their net revenue from or devote 50 percent of their assets to psychedelic drugs and (ii) derivatives that have economic characteristics similar to such securities.

Quantum Biopharma Ltd

Compass Pathways Plc Adr

Gh Research Plc

NRX Pharmaceuticals Inc.

Intra-Cellular Therapies Inc

Atai Life Sciences BV

Alkermes Plc

Vistagen Therapeutics Inc.

Sage Therapeutics, Inc

Neuronetics Inc

ADVISORSHARES PSYCHEDELICS ETF

Throughout the last three months, 22 analysts have evaluated Texas Instruments (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TXN#NASDAQ">TXN</a>), offering a diverse set of opinions from bullish to bearish.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">6</td>
<td align="right">3</td>
<td align="right">10</td>
<td align="right">2</td>
<td align="right">1</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">5</td>
<td align="right">3</td>
<td align="right">7</td>
<td align="right">2</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have recently evaluated Texas Instruments and provided 12-month price targets. The average target is $183.91, accompanied by a high estimate of $225.00 and a low estimate of $125.00. A 8.42% drop is evident in the current average compared to the previous average price target of $200.81. 
<img src="https://www.benzinga.com/files/images/story/2025/1750878014_0.png" alt="price target chart" />
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
The standing of Texas Instruments among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Joshua Buchalter</td>
<td>TD Cowen</td>
<td>Raises</td>
<td>Hold</td>
<td>$200.00</td>
<td>$160.00</td>
</tr>
<tr>
<td>Matthew Prisco</td>
<td>Cantor Fitzgerald</td>
<td>Raises</td>
<td>Neutral</td>
<td>$200.00</td>
<td>$170.00</td>
</tr>
<tr>
<td>Joe Quatrochi</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$190.00</td>
<td>$175.00</td>
</tr>
<tr>
<td>Christopher Danely</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Buy</td>
<td>$220.00</td>
<td>$210.00</td>
</tr>
<tr>
<td>Jay Goldberg</td>
<td>Seaport Global</td>
<td>Announces</td>
<td>Sell</td>
<td>$130.00</td>
<td>-</td>
</tr>
<tr>
<td>Vijay Rakesh</td>
<td>Mizuho</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$170.00</td>
<td>$190.00</td>
</tr>
<tr>
<td>Cody Acree</td>
<td>Benchmark</td>
<td>Lowers</td>
<td>Buy</td>
<td>$200.00</td>
<td>$230.00</td>
</tr>
<tr>
<td>Timothy Arcuri</td>
<td>UBS</td>
<td>Lowers</td>
<td>Buy</td>
<td>$215.00</td>
<td>$225.00</td>
</tr>
<tr>
<td>Joseph Moore</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Underweight</td>
<td>$148.00</td>
<td>$146.00</td>
</tr>
<tr>
<td>Matthew Prisco</td>
<td>Cantor Fitzgerald</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$170.00</td>
<td>$200.00</td>
</tr>
<tr>
<td>Harlan Sur</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$195.00</td>
<td>$230.00</td>
</tr>
<tr>
<td>William Stein</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Hold</td>
<td>$171.00</td>
<td>$195.00</td>
</tr>
<tr>
<td>Joshua Buchalter</td>
<td>TD Securities</td>
<td>Maintains</td>
<td>Hold</td>
<td>$160.00</td>
<td>$160.00</td>
</tr>
<tr>
<td>Brett Fishbin</td>
<td>Keybanc</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$215.00</td>
<td>$250.00</td>
</tr>
<tr>
<td>Joe Quatrochi</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$175.00</td>
<td>$200.00</td>
</tr>
<tr>
<td>Kevin Garrigan</td>
<td>Rosenblatt</td>
<td>Maintains</td>
<td>Buy</td>
<td>$216.00</td>
<td>$216.00</td>
</tr>
<tr>
<td>Tom O'Malley</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Underweight</td>
<td>$125.00</td>
<td>$180.00</td>
</tr>
<tr>
<td>Tore Svanberg</td>
<td>Stifel</td>
<td>Lowers</td>
<td>Hold</td>
<td>$160.00</td>
<td>$200.00</td>
</tr>
<tr>
<td>Vivek Arya</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$176.00</td>
<td>$220.00</td>
</tr>
<tr>
<td>Timothy Arcuri</td>
<td>UBS</td>
<td>Lowers</td>
<td>Buy</td>
<td>$225.00</td>
<td>$250.00</td>
</tr>
<tr>
<td>Christopher Danely</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Buy</td>
<td>$210.00</td>
<td>$235.00</td>
</tr>
<tr>
<td>Tristan Gerra</td>
<td>Baird</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$175.00</td>
<td>$175.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Texas Instruments. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Texas Instruments compared to the broader market.</li>
<li>Price Targets: Understanding forecasts, analysts offer estimates for Texas Instruments's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Texas Instruments's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/TXN/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Texas Instruments analyst ratings.</a>
<h2>Discovering Texas Instruments: A Closer Look</h2>
Dallas-based Texas Instruments generates over 95% of its revenue from semiconductors and the remainder from its well-known calculators. Texas Instruments is the world's largest maker of analog chips, which are used to process real-world signals such as sound and power. Texas Instruments also has a leading market share position in processors and microcontrollers used in a wide variety of electronics applications.
<h3>Financial Insights: Texas Instruments</h3>
Market Capitalization Perspectives: The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.
Revenue Growth: Over the 3M period, Texas Instruments showcased positive performance, achieving a revenue growth rate of 11.14% as of 31 March, 2025. This reflects a substantial increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Information Technology sector.
Net Margin: Texas Instruments's net margin is impressive, surpassing industry averages. With a net margin of 28.98%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): Texas Instruments's ROE stands out, surpassing industry averages. With an impressive ROE of 7.08%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): Texas Instruments's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 3.4% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: Texas Instruments's debt-to-equity ratio surpasses industry norms, standing at 0.78. This suggests the company carries a substantial amount of debt, posing potential financial challenges.
<h2>Understanding the Relevance of Analyst Ratings</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings

22 Analysts Have This To Say About Texas Instruments

Zohran Mamdani is expected to win the New York City Democratic Primary in a <a href="https://www.benzinga.com/news/politics/25/06/46087359/zohran-mamdani-leads-nyc-mayoral-primary-andrew-cuomo-concedes-race">surprising turn of events, </a>defeating former New York Governor Andrew Cuomo.
While the win secures Mamdani a spot on the general election ballot, he still faces a tough road in November's mayoral race.
What Happened: On Tuesday night, Cuomo—backed by several billionaires during the race—quickly congratulated Mamdani on his primary victory. But he also made it clear he hasn't ruled out an independent run in the November election. 

"I said he won the primary election," Cuomo <a href="https://www.nytimes.com/2025/06/25/nyregion/nyc-mayor-election-november.html">told </a>the New York Times. "I said I wanted to look at the numbers and the ranked-choice voting to decide about what to do in the future, because I'm also on an independent line. And that's the decision, that's what I was saying."
With no candidate receiving a 50% majority on Tuesday night, voters&#8217; second-place votes will be counted in a process that eliminates candidates and continues until one remains.
Cuomo's defeat came as a surprise to many. The former governor resigned four years ago amid sexual harassment allegations, which he denied. Backed by billionaires, Cuomo also aligned more closely with the traditional Democratic establishment than Mamdani, a democratic socialist.
Mamdani, 33, has sparked widespread debate with a platform that includes freezing rent, raising taxes on the wealthy, free city bus service, universal child care, and city-owned grocery stores.
Those policies have proven unpopular with the wealthy city residents and could see money poured towards candidates to defeat Mamdani in the November election.
Read Also: <a href="https://www.benzinga.com/news/legal/25/03/44094049/cuomos-mayoral-bid-shakes-up-nyc-race-drawing-major-power-brokers-and-critics-alike">Cuomo&#8217;s Mayoral Bid Shakes Up NYC Race, Drawing Major Power Brokers And Critics Alike</a>
What Happens Next: Mamdani's potential win on Tuesday is no guarantee that he will win in November. Regardless of whether Cuomo jumps in as an Independent, Mamdani will face off against incumbent mayor Eric Adams.
Adams is a Democrat who has been at odds with his party and is choosing to run in the November election as an Independent.
Some Democrats are hoping that Cuomo doesn't run in the general election, as his inclusion could split votes between Cuomo and Adams and secure a path for Mamdani to win the election. The large majority of Democratic voters, who outnumber the Republicans six-to-one, according to the New York Times, could split the vote between multiple candidates.
Another potential option could be a third-party run by someone like Andrew Yang, who previously ran in the New York City mayoral race in 2021 and ran for president in the 2020 election.
Yang established the Forward Party and, according to The Hill, reached out to billionaire Elon Musk as recently as this month to collaborate on a third party.
"We have been of the opinion that America needed a new political party for a number of years," Yang told <a href="https://www.politico.com/news/magazine/2025/06/07/elon-musk-third-party-andrew-yang-interview-00392288">Politico </a>in an interview.
Yang reached out to Musk at a time when Musk was feuding with President Donald Trump and even polled his X followers to see if a third party that represents those who identify in the middle politically should be launched. Over 5.6 million people voted in the <a href="https://x.com/elonmusk/status/1930685402631053403" target="_blank" rel="noopener">poll,</a><a href="https://x.com/elonmusk/status/1930685402631053403"> </a>with 80.4% saying yes, although not all the votes were likely from eligible American voters.
Yang has been supportive of Musk and the potential of a third party, which comes after Musk spent hundreds of millions to help support Trump in the 2024 presidential election.
"I want to work with people that recognize that America's political system has gone from dysfunctional to polarizing to even worse. And at this point, the fastest growing political movement in the United States is independents."
Yang highlighted that Musk has supported candidates that are both Democratic and Republican in the past and like other voters who supported Trump and the "Make America Great Again" movement, could be looking for alternatives going forward.
On Wednesday, Yang <a href="https://x.com/AndrewYang/status/1937858506704539894">tweeted </a>that &#8220;it&#8217;s a new day,&#8221; while sharing several posts about the NYC mayoral race.
While Yang or Cuomo will not necessarily run in the New York City mayoral race, a broader field of independent candidates could split the vote, making this one of the most consequential tests of whether a third party can win a major race.
Current odds on prediction market <a href="https://polymarket.com/event/new-york-city-mayoral-election">Polymarket </a>show Mamdani as the favorite to win the November election at 73.1%, followed by Adams at 22.0%. Cuomo is listed with a current 2.9% chance, but that comes without him declaring an Independent run. Yang is listed with less than a 1% chance of winning, without publicly entering the race.
Another Polymarket prediction market is for whether Cuomo will run as a non-Democrat in the general election, with yes getting 34% of the vote.
On <a href="https://kalshi.com/?live=new-york-city-mayor-election">Kalshi</a>, Mamdani is the favorite at 73%, followed by Adams and 24% and Cuomo at 5%. Yang is not currently listed.
Mamdani's primary win could impact stocks with a heavy presence in New York. Here are several movers <a href="https://x.com/SaraEisen/status/1937905974960062625">highlighted </a>by CNBC's Sara Eisen.
Flagstar Financial (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FLG#NYSE">FLG</a>) is down 5% to $10.63 on Wednesday.
SL Green Realty Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SLG#NYSE">SLG</a>) is down 5% to $58.63 on Wednesday.
Vornado Realty Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VNO#NYSE">VNO</a>) is down 6% to $36.23 on Wednesday.
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/politics/25/06/45807476/mark-cuban-check-marks-elon-musks-idea-of-a-new-political-party-that-represents-the-middle">Mark Cuban Check Marks Elon Musk&#8217;s Idea Of A New Political Party That Represents &#8216;The Middle&#8217;</a></li>
</ul>
Photo: Ron Adar / Shutterstock.com

Politics

Movers

Trading Ideas

Democratic Party Implodes As MAGA Revolts — Can Musk, Yang Build Third Party?

<a href="https://x.com/BitcoinMagazine/status/1937944775820468637">https://x.com/BitcoinMagazine/status/1937944775820468637</a>

News

General

$BTC

Bitcoin Magazine Posts On X "White House Deputy Director said there is an 'accumulation plan' for the US to buy more Bitcoin"

Biogen Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIIB#NASDAQ">BIIB</a>) on Wednesday announced<a href="https://www.globenewswire.com/news-release/2025/06/25/3104985/0/en/Biogen-to-Advance-Investigational-Spinal-Muscular-Atrophy-Asset-to-Registrational-Studies-Based-on-Positive-Interim-Phase-1-Results.html"> in</a> a press release the topline results from the Phase 1 study of salanersen (BIIB115/ION306), an antisense oligonucleotide (ASO) being developed for <a href="https://www.benzinga.com/general/biotech" target="_blank" rel="noreferrer noopener">spinal muscular atrophy (SMA)</a>.
Biogen licensed the global development, manufacturing and commercialization rights for salanersen from Ionis Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IONS#NASDAQ">IONS</a>). Salanersen was discovered by Ionis.
Leveraging the same mechanism of action as Spinraza (nusinersen) but designed to achieve greater potency, salanersen can achieve high efficacy and enable once-a-year dose.
Also Read: <a target="_blank" href="https://www.benzinga.com/m-a/25/06/45949485/supernus-pharma-acquires-maker-of-postpartum-depression-drug-zurzuvae-in-795-million-deal" rel="noreferrer noopener">Supernus Pharma Acquires Maker Of Postpartum Depression Drug Zurzuvae In $795 Million Deal</a>
An interim analysis of the phase one study in participants with SMA who were previously treated with Novartis AG&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVS#NYSE">NVS</a>) gene therapy, Zolgensma (onasemnogene abeparvovec), was conducted to inform the decision on whether to move salanersen forward <a href="https://www.benzinga.com/pressreleases/25/06/g46091748/biogen-to-advance-investigational-spinal-muscular-atrophy-asset-to-registrational-studies-based-on" target="_blank" rel="noreferrer noopener">into registrational studies</a>.
Both dose levels tested, 40 mg and 80 mg, given once a year, were generally well-tolerated and led to substantial slowing of neurodegeneration, as shown by reductions in neurofilament.
Exploratory clinical outcome data show clinically meaningful improvements in function and attainment of new World Health Organization (WHO) milestones over one year.
Interim results are from part B (n=24) in individuals who received either 40 mg or 80 mg salanersen once a year.
In participants with elevated baseline concentrations of neurofilament light chain (NfL), indicating ongoing neurodegeneration, initiation of salanersen led to mean reductions in NfL of 70% at six months, which were sustained through the one-year dosing interval.
Exploratory clinical outcome data were evaluated for the subgroup of participants with at least one year of follow-up during the interim analysis (n=8 participants aged 2-12 who received 40 mg of salanersen). Half (four out of eight) of these participants achieved new WHO motor milestones they could not previously achieve on their own or required assistance, such as walking, crawling, standing or sitting.
Furthermore, these participants experienced clinically meaningful improvements in motor function from baseline to one year, including a 3.3-point (SD 4.46) mean improvement from baseline on the Hammersmith Functional Motor Scale – Expanded (HFMSE) and a 5.3 point (SD 4.75) improvement on the Revised Upper Limb Module (RULM).
Biogen is currently engaging with global health authorities regarding the design of the phase 3 studies.
Earlier in June, Biogen initiated dosing in the BRAVE phase 3 study to evaluate the efficacy and safety of omaveloxolone in children with Friedreich ataxia (FA) between <a href="https://www.benzinga.com/pressreleases/25/06/g45992415/biogen-initiates-phase-3-pediatric-study-of-omaveloxolone-for-the-treatment-of-friedreich-ataxia" target="_blank" rel="noreferrer noopener">the ages of 2 to &lt;16</a>.
Both non-ambulatory and ambulatory participants may qualify for the study.
Currently, omaveloxolone is commercialized under the brand name Skyclarys in over 40 countries, including the U.S. and the European Union, and is the only approved product for FA in adults and adolescents aged 16 years and older.
BIIB Price Action: Biogen stock is up 0.58% at $127.04 at publication on Wednesday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/tech/25/06/46097512/robotaxi-roll-out-tesla-uber-and-waymo-take-diverging-roads-to-autonomy" target="_blank" rel="noreferrer noopener">Robotaxi Roll Out: Tesla, Uber And Waymo Take Diverging Roads To Autonomy</a></li>
</ul>
Photo: New Africa via Shutterstock

Biotech

Large Cap

Health Care

BIIB

IONS

Biogen-Ionis Partnered Drug Shows Benefit In Children With Spinal Muscular Atrophy Previously Treated With Novartis' Zolgensma

WIIM

ONDS

ONDS stock has given up its prior gain. Ondas Holdings shares were trading higher after announcing a partnership with Detroit Manufacturing Systems to boost U.S. drone production.

Although glucagon-like peptide-1 (GLP-1) agonists have shown promising results in reducing weight and cardiovascular risks, new data reveals that many U.S. adults struggle to stay on <a target="_blank" href="https://www.benzinga.com/topic/weight-loss" rel="noreferrer noopener">long-term treatment</a>.
While newer obesity-indicated GLP-1 therapies, such as semaglutide and tirzepatide, are increasingly used, poor persistence rates threaten the clinical and economic benefits of these medications.
Novo Nordisk A/S' (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) semaglutide is the main input in Ozempic and Wegovy, and tirzepatide is a key ingredient in Eli Lilly &amp; Co's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) Mounjaro and Zepbound.
Also Read: <a target="_blank" href="https://www.benzinga.com/markets/large-cap/25/06/46076029/novos-india-move-could-reshape-the-weight-loss-drug-war-with-eli-lilly" rel="noreferrer noopener">Novo's India Move Could Reshape The Weight-Loss Drug War With Eli Lilly</a>
GLP-1 agonists have been linked to 10% to 20% weight loss in clinical trials, with some studies also showing reduced cardiovascular events in individuals without diabetes.
Yet, despite these benefits, long-term adherence remains a major hurdle. A 2023 real-world study by Prime Therapeutics found that just 27% of users remained adherent for one year, and only 15% persisted for two years. At three years, only 8.1% of users were still on treatment.
Even the best-performing drug, Wegovy, had a three-year persistence rate of just 14.3%.
The three-year analysis included 5,780 individuals continuously enrolled in a health plan after initiating GLP-1 treatment for obesity.
The group had a mean age of 46.7 years, and nearly 80% were women. Persistence rates varied widely by medication, from 14.3% with weekly semaglutide (Wegovy) to 2.5% with daily liraglutide (Victoza).
Over three years, only 12.5% of users met the standard for adherence based on medication possession, and more than one-third switched to a different GLP-1 therapy.
However, more recent <a target="_blank" href="https://www.primetherapeutics.com/w/prime-therapeutics-leading-research-shows-only-1-in-12-remain-on-a-glp-1-drug-for-obesity-at-three-years" rel="noreferrer noopener">data</a> suggests that persistence may be improving. In a separate year-over-year analysis involving 23,025 individuals initiating high-potency GLP-1s—Wegovy and Zepbound—one-year persistence rose from 33.2% in 2021 to 62.7% in 2024.
Tirzepatide (Zepbound), introduced in late 2023, had one-year persistence rates of over 62% in both 2023 and 2024.
This trend toward better short-term adherence is attributed to reduced supply shortages, improved dose escalation strategies, better side-effect management, and support programs.
Nonetheless, experts <a target="_blank" href="https://www.primetherapeutics.com/documents/d/primetherapeutics/prime-therapeutics_glp-1-therapy-to-treat-obesity-among-members-without-diabetes_three-year-persistence" rel="noreferrer noopener">caution</a> that poor long-term persistence among early adopters signals potential investment risk and limits the therapies' full clinical impact.
Further research is needed to understand why so many users discontinue treatment and whether newer approaches can sustain adherence over the long term.
Price Action: LLY stock is up 1.92% at $792.37, and NVO stock is down 5.03% at $67.17 at the last check on Wednesday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/fda/25/06/46101643/did-the-fda-make-a-mistake-sareptas-elevidys-approval-under-scrutiny">Did The FDA Make A Mistake? Sarepta&#8217;s Elevidys Approval Under Scrutiny</a></li>
</ul>
Photo by Tobias Arhelger via Shutterstock

US Adults Struggle With Long-Term Use Of Obesity Drugs Like Wegovy, Data Shows

<a href="https://www.cnbc.com/2025/06/25/nvidia-shareholder-meeting-2025-robots.html">https://www.cnbc.com/2025/06/25/nvidia-shareholder-meeting-2025-robots.html</a>

NVDA

'Nvidia CEO says robotics is chipmaker's biggest opportunity after AI'- CNBC

Despite recent volatility, long-term holders of Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>), Ethereum (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/eth/usd">ETH</a>), and XRP (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/xrp/usd">XRP</a>), Dogecoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/doge/usd">DOGE</a>) are enjoying substantial gains — a payoff for their patience <a href="https://www.benzinga.com/markets/cryptocurrency/25/05/45335892/decade-old-bitcoin-whale-emerges-transfers-207-51-million-btc-with-nearly-112000-profit">during earlier market cycles.</a>
What Happened: According to new <a href="https://x.com/santimentfeed/status/1937569460896092327">data</a> from Santiment, 94.5% of Bitcoin's circulating supply is currently in profit, followed by Ethereum at 88.7%, reflecting strong investor conviction. 
XRP (65.1%), Dogecoin at 64.7%, and Chainlink (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/link/usd">LINK</a>) at 59.4% also show solid profitability, though these levels suggest a more balanced sentiment between caution and optimism.
Cardano (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/ada/usd">ADA</a>), however, lags with only 46.5% of its supply in profit, indicating that a majority of holders are underwater. 
While this signals bearish sentiment among investors who bought near previous highs, it could also represent a potential value opportunity if bullish momentum returns in the second half of 2025. 
This implies undervaluation and more of a bearish sentiment from jaded investors who bought at a higher price than where ADA sits currently.
Also Read: <a href="https://www.benzinga.com/crypto/cryptocurrency/25/06/46101110/bitcoin-senator-cynthia-lummis-lauds-white-houses-real-enthusiasm-for-crypto-legislation">&#8216;Bitcoin Senator&#8217; Cynthia Lummis Lauds White House&#8217;s &#8216;Real Enthusiasm&#8217; For Crypto Legislation</a>
Why It Matters: High profitability levels often signal strong market confidence, but they can also precede profit-taking corrections, particularly when fear and greed rapidly alternate. 
Santiment <a href="https://x.com/santimentfeed/status/1937892738684576217">observed</a> that Bitcoin has recently climbed back to $108,200, buoyed by positive reaction to the ceasefire between Israel and Iran, which remains intact.
Meanwhile, Chainlink's 11% surge today <a href="https://x.com/santimentfeed/status/1937601918819336673">came</a> as the number of LINK holders hit a record 769,380. 
Despite this, active wallets over the past year are down 17.3%, signalling a shift toward long-term accumulation.
Ethereum's outlook also remains optimistic, with trader Ted Pillows <a href="https://x.com/TedPillows/status/1937829374134247475">noting </a>that whales are positioning long, suggesting bullish expectations into year-end.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/crypto/cryptocurrency/25/06/46091840/bitcoin-ethereum-xrp-dogecoin-hold-gains">Bitcoin, Ethereum, XRP, Dogecoin Hold Gains As Crypto ETF Inflows Continue</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$ADA

$DOGE

$ETH

$LINK

$XRP

Bitcoin, Ethereum, XRP Holders Sitting On Profits, While Dogecoin Trails: Report

Shares of Advanced Micro Devices Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMD#NASDAQ">AMD</a>) are trading higher Wednesday, adding to gains of more than 25% over the past month. Here&#8217;s a look at <a href="https://www.benzinga.com/trading-ideas/movers/25/06/46080942/why-amd-stock-is-soaring-tuesday">what&#8217;s going on</a>.
What To Know: AMD shares are rallying this week after the chipmaker announced a new collaboration with HCLTech aimed at accelerating enterprise digital transformation. The two companies plan to establish joint innovation labs focused on developing solutions in AI, digital infrastructure and cloud computing.
AMD CEO Lisa Su said the partnership will help deliver cutting-edge technology to give businesses the solutions they need to accelerate innovation. 
&#8220;Combining HCLTech&#8217;s expertise in digital transformation with our industry-leading EPYC, Instinct and Ryzen PRO processors will enable us to provide enterprises with customized, future-ready solutions that maximize the potential of AI, cloud computing and advanced analytics,&#8221; Su said.
Semiconductor stocks have seen strong momentum in recent trading sessions following easing tensions in the Middle East. AMD also got a boost this week after Melius Research analyst Ben Reitzes upgraded AMD from Hold to Buy and raised the price target from $110 to $175, reflecting growing confidence in the company&#8217;s positioning in the AI and enterprise computing space.
Earlier this month, multiple analysts came out with <a href="https://www.benzinga.com/trading-ideas/movers/25/06/45955190/amd-stock-is-soaring-monday-whats-going-on">positive updates</a> after AMD unveiled multiple new products at its "Advancing AI"  event. Piper Sandler raised its target to $140 and reiterated an Overweight rating. Roth Capital and Evercore ISI also lifted their targets to $150 and $144, respectively, while Rosenblatt recently maintained a Buy rating with a $200 target.
Is AMD A Good Stock To Buy?
Wall Street analysts view AMD on the whole as a Outperform, given the history of coverage over the past three months. 
But looking at how the market as a whole thinks of the stock, you can reference historical price action for views on whether investors feel strongly about the stock one way or another. In the past three months, AMD rose 35.59%, which indicates that opinion improved on the business and how attractive it is to own based on either its stock price, or underlying fundamentals, like revenue, which rose 35.9% over the past year.
AMD Price Action: AMD shares were up 3.17% at $142.82 at the time of writing, according to <a href="https://pro.benzinga.com/dashboard?new_user=False&amp;backend=google-oauth2">Benzinga Pro.</a>
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/analyst-stock-ratings/analyst-color/25/06/46099022/best-ai-stocks-nvidia-semiconductors-top-performers">The AI Rally Just Flipped—These Stocks Are Now Outgunning Nvidia</a></li>
</ul>
Image via Shutterstock.

What's Going On With AMD Shares Today?

H.C. Wainwright analyst Heiko F. Ihle reiterated a Buy rating on U.S. Gold Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/USAU#NASDAQ">USAU</a>) <a href="https://www.benzinga.com/quote/USAU/analyst-ratings" target="_blank" rel="noreferrer noopener">with a price forecast of $15</a>.
Ihle highlighted that U.S. Gold Corp. released key details on its upcoming Feasibility Study, or FS on June 24, following the updated Pre-Feasibility Study published in February 2025.
The analyst noted that the FS will include a site-specific Association for Advancement of Cost Engineering (AACE) Class 3 cost estimate and a detailed execution plan aimed at aligning with the current project timeline.
Also Read: <a href="https://www.benzinga.com/markets/commodities/25/04/44754594/gold-miners-rally-as-bullion-hits-3212-record-trump-tariffs-fuel-over-20-year-to-date-surge-across-sector" target="_blank" rel="noreferrer noopener">Gold Miners Rally As Bullion Hits $3,212: Trump Tariffs Fuel Over 20% Year-To-Date Surge Across Sector</a>
The FS is expected to be finalized by the fourth quarter, and he writes it will outline a practical and appealing path forward for the fully permitted CK Gold Project.
This apart, Ihle stated that his valuation of U.S. Gold Corp. is based on a discounted cash flow (DCF) model for the CK Gold Project, using a 15% discount rate, consistent with other early-stage mining projects in top-tier jurisdictions.
His DCF model yields a value of $206.9 million, or $11.69 per share, for the CK asset. He assigns an additional $50 million combined value for the Challis ($28 million), Keystone ($20 million), and Orevada ($2 million) projects.
Ihle also noted that these non-core asset estimates appear increasingly conservative given current spot gold prices of $3,325 per ounce.
Ihle highlighted that a recent $7.3 million cash boost from exercised warrants should support near-term operational needs as the company works toward future milestones.
The analyst emphasized that U.S. Gold remains well-positioned to drive long-term shareholder value, especially amid favorable gold prices and recent progress.
He further highlighted the company&#8217;s impending inclusion in the Russell 3000 and Russell 2000 indexes, effective June 30, 2025. This move is poised to significantly increase trading volume as index funds adjust their portfolios to include the stock.
Price Action: USAU shares are trading lower by 1.76% to $12.60 at last check Wednesday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/tech/25/06/46096528/nasdaq-100-record-highs-rally-historical-performance" target="_blank" rel="noreferrer noopener">Nasdaq 100 Hits Record Highs After 30% Rally: History Suggests It&#8217;s Not Done Yet</a></li>
</ul>
Photo via Shutterstock

Analyst Color

Equities

Price Target

Reiteration

Markets

USAU

U.S. Gold Is Fortified By Assets, $7.3 Million Boost, And Soaring Gold: Analyst

<a href="https://www.bloomberg.com/news/articles/2025-06-25/russia-is-open-to-new-output-hike-if-opec-decides-it-s-needed">https://www.bloomberg.com/news/articles/2025-06-25/russia-is-open-to-new-output-hike-if-opec-decides-it-s-needed</a>

'Russia Is Open to New Output Hike If OPEC+ Decides It's Needed'- Bloomberg

Surf Air Mobility Inc.(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SRFM#NYSE">SRFM</a>) (the "Company"), a leading regional air mobility platform, announced today that it has entered into definitive agreements for the purchase and sale of 10,800,002 shares of common stock (or pre-funded warrants in lieu thereof) at a purchase price of $2.50 per share (or pre-funded warrant in lieu thereof) in a registered direct offering. The offering is expected to close on or about June 26, 2025, subject to the satisfaction of customary closing conditions.
The gross proceeds to the Company from the offering are expected to be approximately $27 million, before deducting the placement agent's fees and other offering expenses payable by the Company. The Company currently intends to use the net proceeds from the offering to pay down certain indebtedness and for general corporate purposes. &nbsp;

Offerings

SRFM

Surf Air Mobility Announces $27M Registered Direct Offering At $2.50/Shr

<a href="https://techcrunch.com/2025/06/25/meta-is-adding-ai-powered-summaries-to-whatsapp/">https://techcrunch.com/2025/06/25/meta-is-adding-ai-powered-summaries-to-whatsapp/</a>

'Meta is adding AI-powered summaries to WhatsApp'- Techcrunch

BLNE

BLNE stock has given up its prior gain. Beeline Holdings shares were trading higher after the company announced its subsidiary, Beeline Title holdings, closed its first crypto real estate transactions.

ESRT

Shares of NYC-based REIT stocks are trading lower amid Zohran Mamdani's lead in the Democratic mayoral primary.

RITR

Reitar Logtech Shares Halted On Circuit Breaker To The Upside, Stock Now Up 18.9%

Shares of POET Technologies Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/POET#NASDAQ">POET</a>) are trading higher Wednesday. The company received the 2025 AI Hardware Innovation Award and recently announced a new manufacturing partnership <a href="https://www.benzinga.com/pressreleases/25/06/g46095879/poet-wins-ai-hardware-innovation-award-in-2025-ai-breakthrough-awards">aimed at scaling production.</a>
What To Know: Poet&#8217;s Teralight optical engine line won the "AI Hardware Innovation Award" at the 8th annual AI Breakthrough Awards. 
Teralight features a compact, wafer-level chip-scale design that integrates transmit and receive optical engines, supporting AI and hyperscale data center applications. The award recognized Teralight's architecture for improving signal quality and energy efficiency while reducing complexity in module design.
The stock may also be gaining on continued momentum from Tuesday. Poet Technologies disclosed it signed a <a href="https://www.benzinga.com/pressreleases/25/06/g46070871/poet-signs-manufacturing-agreement-with-nationgate-solutions-in-malaysia">manufacturing agreement</a> with NationGate Solutions in Malaysia. NationGate will assemble and test Poet&#8217;s optical engines, including components designed for a key customer targeting hyperscale data center markets. This agreement follows an earlier partnership with Globetronics and is intended to strengthen Poet&#8217;s production capabilities and supply chain resilience.
Poet Technologies confirmed it has already shipped its backlog of 800G samples and expects to ship its 1.6T samples in the third quarter of 2025. Both Malaysian facilities are undergoing final qualification. The increased demand and growing number of customer engagements potentially suggest continued interest in Poet&#8217;s integrated photonics solutions for AI and high-performance computing applications.
POET Price Action: Poet Technologies shares were up 19.5% at $5.15 at the time of writing Wednesday, according to <a href="https://pro.benzinga.com/dashboard?new_user=False&amp;backend=google-oauth2">Benzinga Pro.</a>
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/analyst-stock-ratings/analyst-color/25/06/46099022/best-ai-stocks-nvidia-semiconductors-top-performers">The AI Rally Just Flipped—These Stocks Are Now Outgunning Nvidia</a></li>
</ul>
Image via Shutterstock.

POET

What'g Going On With POET Technologies Stock Today?

The Food and Drug Administration (FDA) on Tuesday said it is investigating the risk of acute liver failure with serious outcomes, including hospitalization and death, following Sarepta Therapeutics, Inc.&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRPT#NASDAQ">SRPT</a>) Elevidys treatment and evaluating the need for further regulatory action.
Since approval, the agency has <a target="_blank" href="https://www.fda.gov/vaccines-blood-biologics/safety-availability-biologics/fda-investigating-deaths-due-acute-liver-failure-non-ambulatory-duchenne-muscular-dystrophy-patients" rel="noreferrer noopener">received</a> two reports of fatal acute liver failure following treatment of non-ambulatory pediatric male patients with Duchenne Muscular Dystrophy (DMD) with Elevidys (delandistrogene moxeparvovec-rokl), an adeno-associated virus vector-based gene therapy.
The two reported deaths in non-ambulatory DMD patients appear to be related to treatment with Elevidys. Reports were received from clinical trial and postmarketing data.
Also Read: <a href="https://www.benzinga.com/news/fda/25/06/45945282/sarepta-therapeutics-stock-plummets-over-40-on-second-fatal-case-linked-to-its-gene-therapy">Sarepta Therapeutics Stock Plummets Over 40% On Second Fatal Case Linked To Its Gene Therapy</a>
In these two cases, the patients presented with elevated transaminases and were hospitalized less than two months after treatment with Elevidys.
On Wednesday, HC Wainwright reiterated its Sell rating for Sarepta, maintaining a <a href="https://www.benzinga.com/analyst-stock-ratings/downgrades/25/06/46034962/analyst-downgrades-sarepta-as-elevidys-safety-clouds-future-demand">price forecast of $10</a>. Analyst Mitchell Kapoor stated his belief that &#8220;it is highly likely that the FDA will at least require updated language to the USPI to denote the risk of liver failure or death.&#8221;
The analyst says the worst-case scenario for Sarepta would be if the FDA ultimately required the company to withdraw Elevidys from the U.S. market.
Kapoor underscored a critical risk for Sarepta, stating, &#8220;If Elevidys were to be withdrawn, we see little intrinsic value remaining in the company.&#8221; 
Kapoor further highlighted the FDA as a potential headwind, noting that Center for Biologics Evaluation and Research (CBER) head Vinay Prasad has previously voiced strong disapproval of Peter Marks&#8217; initial approval of Elevidys. 
This established skepticism from Dr. Prasad, even prior to the recent reports of liver failure deaths, suggests a likely reluctance to support Sarepta&#8217;s continued marketing of Elevidys.
For a broader perspective on Sarepta&#8217;s outlook, explore how other <a href="https://www.benzinga.com/quote/SRPT/analyst-ratings">analysts view the stock</a>.
Price Action: SRPT stock is trading lower by 9.96% to $17.09 at last check Wednesday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/legal/25/06/46098969/bristol-myers-faces-scrutiny-for-allegedly-rigging-market-on-2b-cancer-drug" target="_blank" rel="noreferrer noopener">Bristol Myers Faces Scrutiny For Allegedly Rigging Market On $2B Cancer Drug</a></li>
</ul>
Photo by Tada Images via Shutterstock

SRPT

Did The FDA Make A Mistake? Sarepta's Elevidys Approval Under Scrutiny

11 analysts have shared their evaluations of Waste Management (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WM#NYSE">WM</a>) during the recent three months, expressing a mix of bullish and bearish perspectives.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">3</td>
<td align="right">3</td>
<td align="right">5</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $254.55, with a high estimate of $277.00 and a low estimate of $229.00. Marking an increase of 7.22%, the current average surpasses the previous average price target of $237.40. 
<img src="https://www.benzinga.com/files/images/story/2025/1750874473_0.png" alt="price target chart" />
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
A comprehensive examination of how financial experts perceive Waste Management is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Devin Dodge</td>
<td>BMO Capital</td>
<td>Raises</td>
<td>Market Perform</td>
<td>$245.00</td>
<td>$241.00</td>
</tr>
<tr>
<td>Noah Kaye</td>
<td>Oppenheimer</td>
<td>Raises</td>
<td>Outperform</td>
<td>$255.00</td>
<td>$251.00</td>
</tr>
<tr>
<td>Rob Wertheimer</td>
<td>Melius Research</td>
<td>Announces</td>
<td>Buy</td>
<td>$263.00</td>
<td>-</td>
</tr>
<tr>
<td>Tami Zakaria</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$277.00</td>
<td>$225.00</td>
</tr>
<tr>
<td>Bryan Burgmeier</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Buy</td>
<td>$271.00</td>
<td>$260.00</td>
</tr>
<tr>
<td>Sabahat Khan</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Sector Perform</td>
<td>$229.00</td>
<td>$227.00</td>
</tr>
<tr>
<td>David Manthey</td>
<td>Baird</td>
<td>Raises</td>
<td>Neutral</td>
<td>$245.00</td>
<td>$235.00</td>
</tr>
<tr>
<td>Jon Windham</td>
<td>UBS</td>
<td>Raises</td>
<td>Neutral</td>
<td>$250.00</td>
<td>$240.00</td>
</tr>
<tr>
<td>Wesley Brooks</td>
<td>HSBC</td>
<td>Raises</td>
<td>Buy</td>
<td>$265.00</td>
<td>$210.00</td>
</tr>
<tr>
<td>Jon Windham</td>
<td>UBS</td>
<td>Raises</td>
<td>Neutral</td>
<td>$240.00</td>
<td>$230.00</td>
</tr>
<tr>
<td>Konark Gupta</td>
<td>Scotiabank</td>
<td>Raises</td>
<td>Sector Outperform</td>
<td>$260.00</td>
<td>$255.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Waste Management. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Waste Management compared to the broader market.</li>
<li>Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of Waste Management's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Waste Management's market standing. Stay informed and make data-driven decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/WM/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Waste Management analyst ratings.</a>
<h2>Discovering Waste Management: A Closer Look</h2>
WM ranks as the largest integrated provider of traditional solid waste services in the United States, operating 263 active landfills and about 332 transfer stations. The company serves residential, commercial, industrial, and medical end markets and is also a leading recycler in North America.
<h3>Understanding the Numbers: Waste Management's Finances</h3>
Market Capitalization: Exceeding industry standards, the company's market capitalization places it above industry average in size relative to peers. This emphasizes its significant scale and robust market position.
Positive Revenue Trend: Examining Waste Management's financials over 3M reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 16.65% as of 31 March, 2025, showcasing a substantial increase in top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Industrials sector.
Net Margin: Waste Management's net margin is impressive, surpassing industry averages. With a net margin of 10.58%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): Waste Management's ROE stands out, surpassing industry averages. With an impressive ROE of 7.54%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of 1.43%, the company showcases effective utilization of assets.
Debt Management: The company faces challenges in debt management with a debt-to-equity ratio higher than the industry average. With a ratio of 2.76, caution is advised due to increased financial risk.
<h2>How Are Analyst Ratings Determined?</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

What Analysts Are Saying About Waste Management Stock

Morgan Stanley analyst Pamela Kaufman maintains Ardagh Metal Packaging (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMBP#NYSE">AMBP</a>) with a Equal-Weight and raises the price target from $3.5 to $4.1.

Comments

AdvisorShares Psychedelics ETF

뉴스

에 대한 최신 뉴스 AdvisorShares Psychedelics ETF (ARCA:PSIL)

뉴스

파트너 / 기고자

벤징가 글로벌